Oncology Views & Analysis

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

Views & Analysis

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers.

Views & Analysis

Dreaming big with small molecules

Clovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved and on the market in less than a decade.

Oncology

approximate the DNA molecule on a blue background

Has the NHS joined the biosimilars revolution?

Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Clark, Napp’s director of biosimilars.

Views & Analysis

How the NHS got ahead of the curve with CAR-T

The UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies.

Views & Analysis

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Merck KGaA's bold new approach to cancer immunotherapy

Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.

AstraZeneca looks to CRISPR to boost success rates

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Dreaming big with small molecules

Has the NHS joined the biosimilars revolution?

How the NHS got ahead of the curve with CAR-T

Merck KGaA's bold new approach to cancer immunotherapy

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

Views & Analysis

Editor's Picks